DRUG DISCOVERY AND CLINIC

DRUG DISCOVERY AND CLINIC: HDHODH INHIBITORS TO FIGHT LEUKEMIA

The company, a spin-off from the University of Turin, has developed a molecule with antitumor purposes belonging to the family of HDHODH inhibitors.

To date, the main tests conducted by the company, both in vitro and in vivo, have been directed towards the tumor form of Acute Myeloid Leukemia (AML), and other in vitro tests have been carried out with promising results on some forms of solid tumors (including Triple Negative Breast Cancer).

The company’s goal is therefore aimed at developing a technological platform aimed at developing treatments for leukemias and solid tumors.

The company is initiating a collaboration with the Catholic University of the Sacred Heart to test its molecule on pediatric Glioblastoma (currently incurable).

The team, qualified and multidisciplinary, includes Prof. Giuseppe Saglio, Prof. Giovanni Martinelli, Prof. Donatella Boschi, and Prof. Marco Lucio Lolli.

Utopia invested in October 2022.

I

www.ddcpharmaceutical.com